Full-Time

Clinical Operations Senior Manager

Clinical Process Owner

Posted on 9/7/2026

Precision AQ

Precision AQ

501-1,000 employees

Data-driven drug access and launches

No salary listed

Remote in UK

Remote

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Biostatistics

Get referred to Precision AQ

See people who can refer or advise you

Requirements
  • A bachelor's degree in life sciences, healthcare, clinical research, business, or a related field; equivalent experience may be considered.
  • At least 5+ years of progressive clinical research or clinical operations experience in a contract research organization, pharmaceutical, biotechnology, or global clinical outsourcing environment.
  • Proven experience leading complex cross-functional or global process improvement initiatives from assessment and design through implementation and effectiveness evaluation within a contract research organization environment.
  • Strong knowledge of clinical trial operations, clinical monitoring, site management, and cross-functional trial delivery processes.
  • Strong knowledge of International Council for Harmonisation Good Clinical Practice, regulatory expectations, quality standards, and inspection readiness principles.
  • Demonstrated ability to influence stakeholders, facilitate decisions, resolve conflicting requirements, and drive outcomes in a matrix organization.
Responsibilities
  • Serve as the Clinical Process Owner for Clinical Operations processes, ensuring effective governance, clear accountability, lifecycle management, and alignment across regions and functions.
  • Lead the development, review, harmonization, implementation, and maintenance of Clinical Operations standard operating procedures, work instructions, tools, templates, and related documentation.
  • Identify and resolve process gaps, duplication, inconsistencies, conflicting requirements, and unnecessary complexity to establish clear, practical, and scalable ways of working.
  • Translate regulatory requirements, International Council for Harmonisation Good Clinical Practice principles, quality standards, audit and inspection findings, corrective and preventive actions, operational data, and stakeholder feedback into effective process solutions.
  • Lead and represent cross-functional process governance and decision-making, partnering with Clinical Operations, Quality Assurance, Regulatory, Project Management, Data Management, Biostatistics, Medical, Training, and other relevant functions.
  • Lead process implementation and change management, including impact assessment, stakeholder engagement, training and communication requirements, adoption monitoring, and evaluation of process effectiveness.
  • Act as a senior Clinical Operations subject matter expert for strategic initiatives, audits, inspections, corrective and preventive actions, process assessments, operational improvement activities, and business development support, including providing Clinical Operations input for proposals, budgets, contracts, and bid defense meetings, and representing Clinical Operations process capabilities, delivery models, and operational strengths to prospective clients.
Desired Qualifications
  • Demonstrated experience owning or leading the development, harmonization, implementation, and lifecycle management of Clinical Operations standard operating procedures, work instructions, and related controlled documentation.
  • Experience with process mapping, change management, Lean, or continuous improvement methodologies.
  • Expert understanding of Clinical Operations processes and their cross-functional interfaces.
  • Ability to interpret regulatory and quality requirements and translate them into clear, proportionate, and operationally practical processes.

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 17, 2026 hires Yahya Anvar and Emma Hawe deepen AI and HTA capabilities.
  • August 12, 2026 Candice Subero hire boosts marketing-led customer engagement and commercial growth.
  • Precision AQ’s 2025 Phluence investment advances agentic patient solutions, reducing post-Rx service costs.

What critics are saying

  • Precision AQ reported $314.5 million revenue in 2024, down 7%, signaling slower growth.
  • Phluence integration in November 2025 risks distracting teams while AI patient-service economics remain unproven.
  • If pharma shifts to in-house AI access tools, Precision AQ’s HUB model weakens.

What makes Precision AQ unique

  • Precision AQ works with all top 30 pharma companies and 350+ active engagements in 2026.
  • Its 2024 rebrand unified pricing, HEOR, medical affairs, and omnichannel capabilities under one platform.
  • Precision AQ has launched over 450 drugs, creating embedded launch expertise across therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...